


# Nelarabine plus chemo viable in children with T-cell ALL

June 29 2012

---



Treatment of children with newly-diagnosed T-cell acute lymphoblastic leukemia with nelarabine, in addition to an intensive Berlin-Frankfurt-Münster 86-based chemotherapy regimen, is feasible and safe, according to a study published online June 25 in the *Journal of Clinical Oncology*.

(HealthDay) -- Treatment of children with newly-diagnosed T-cell acute lymphoblastic leukemia (T-ALL) with nelarabine, in addition to an intensive Berlin-Frankfurt-Münster (BFM) 86-based chemotherapy regimen, is feasible and safe, according to a study published online June 25 in the *Journal of Clinical Oncology*.

Kimberly P. Dunsmore, M.D., of the University of Virginia Health System in Charlottesville, and colleagues conducted a study involving children with newly-diagnosed T-ALL to assess the feasibility and safety of adding nelarabine to a chemotherapy regimen. In stage one, 12 participants with a slow early response (SER) received chemotherapy plus nelarabine and 16 patients with a rapid early response (RER)

received chemotherapy without nelarabine. In stage two, 10 patients with SER received six five-day courses of nelarabine, while 12 SER and 38 RER patients received nelarabine once daily.

The researchers found that nelarabine-treated patients exhibited fewer neutropenic infections compared with non-nelarabine-treated patients (42 versus 81 percent). Five-year event-free survival (EFS) for patients with SER was 73 percent for 11 stage-one patients treated with nelarabine and 67 percent for 22 patients treated with nelarabine. For RER patients, the five-year EFS was 69 percent for 16 stage-one patients treated without nelarabine and 74 percent for 38 patients treated with nelarabine. For all 70 patients receiving nelarabine, the five-year EFS was 73 percent, compared with 69 percent for the 16 patients treated without nelarabine.

"Addition of nelarabine to a BFM 86-based [chemotherapy regimen](#) was well tolerated and produced encouraging results in pediatric patients with T-ALL, particularly those with a SER, who have historically fared poorly," the authors write.

One author disclosed financial ties to Becton-Dickinson Biosciences. The study was partially funded by GlaxoSmithKline, which provided nelarabine.

[Abstract](#)

[Full Text \(subscription or payment may be required\)](#)

Copyright © 2012 [HealthDay](#). All rights reserved.

Citation: Nelarabine plus chemo viable in children with T-cell ALL (2012, June 29) retrieved 19 April 2024 from <https://medicalxpress.com/news/2012-06-nelarabine-chemo-viable-children-t-cell.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.